Initiating warfarin therapy

Annals of Pharmacotherapy

Volumn 37, Issue 6, 2003, Pages 905-908

  Dager, William E ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; WARFARIN;

ANTICOAGULATION; BLEEDING; COMPUTER PROGRAM; DOSE RESPONSE; DRUG SENSITIVITY; HUMAN; NOMOGRAM; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOSIS;

EID: 0037809557     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D038     Document Type: Review

References (26)

1. Roberts GW, Helboe T, Nielsen CBM, Gallus AS, Jensen I, Cosh D, et al. Assessment of an age-adjusted warfarin initiation protocol. Ann Pharmacother 2003;37:799-803. DOI 10.1345/aph.1A372
2. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, et al. Managing oral anticoagulant therapy. Chest 2001:119(suppl):22S-38S.
3. Harrison L, Johnston M, Massicotte PM, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-6.
4. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(suppl):8S-21S.
5. Ma MK, Woo MH, McLeod HL. Genetic basis of drug metabolism. Am J Health Syst Pharm 2002;59:2061-9.
6. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variations and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-8.
7. Kayser SR, Dang MT, Hambleton J. The influence of racial background on warfarin dosage requirement (abstract). Blood 2002;100:501a.
8. Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998;63:519-28.
9. Lee J, Lee B, Kim K, Ahn H, Suh O, Lee M, et al. Factors affecting warfarin therapy following cardiac valve surgery. Ann Pharmacother 2002; 36:1845-50. DOI 10.1345/aph.1A431
10. Hawk TL, Havrda DE. Effect of stress on international normalized ratio during warfarin therapy. Ann Pharmacother 2002;36:617-20. DOI 10.1345/aph.1A263
11. Fennerty A, Dolben J, Thomas P, Backhouse G, Bentley DP, Campbell IA, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. BMJ 1984;288:1268-70.
12. Optimal oral anticoagulation therapy in patients with nonrheumatic atrial fibrillation and recent onset cerebral ischemia. European Atrial Fibrillation Trial Study Group. N Engl J Med 1995;333:5-10.
13. Stroke Prevention in Atrial Fibrillation study. Final results. Circulation 1991;84:527-39.
14. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51.
15. WHO Expert Committee on Biological Standardization. 33rd report. Technical report series no. 687. Geneva: World Health Organization, 1983:81.
16. White RH, Zhou H, Romano PS. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thrombolism. Arch Intern Med 1998;158:1005-10.
17. Kovacs MJ, Anderson DA, Wells PS. Prospective assessment of a nomogram for the initiation of oral anticoagulation therapy for outpatient treatment venous thromboembolism. Pathophysiol Haemost Thromb 2002; 32:131-3.
18. Kovacs MJ, Wells PS, Anderson D, Morrow B, Florack P, Burton E, et al. Randomized prospective comparison of 5mg vs 10mg dosing nomograms for initiation of oral anticoagulation therapy for acute venous thromboembolism (abstract P806). Presented at the XVIII Congress of the International Society on Thrombosis and Haemostatis meeting, July 6-12, 2001.
19. Gedge J, Orme S, Hampton KK, Channer KS, Hendra TJ. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing 2000;29:31-4.
20. Pengo V, Biasiolo A, Pegoraro C. A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation. Am J Cardiol 2001;88:1214-6.
21. White RH, Hong R, Venook AP, Daschbach MM, Murray W, Mungall DR, et al. Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing. J Gen Intern Med 1987;2:141-8.
22. Mamdani MM, Racine E, McCreadie S, Zimmerman C, O'Sullivan TL, Jensen G, et al. Clinical and economic effectiveness of an inpatient anticoagulation service. Pharmacotherapy 1999;19:1064-74.
23. Dager WE, Branch JM, King JH, White RH, Quan RS, Musallam NA, et al. Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist-managed anticoagulation service. Ann Pharmacother 2000;34:567-72. DOI 10.1345/aph.18192
24. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulation therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-7.
25. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-74.
26. Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ 2002;325:1073-5.